Niranib (Niraparib) 100 mg
Niranib (Niraparib 100 mg) is a potent poly (ADP-ribose) polymerase (PARP) inhibitor used for ovarian cancer maintenance therapy.
Manufacturer: Everest Pharmaceuticals. A generic equivalent to Zejula.
Mechanism of Action:
Niraparib blocks the PARP enzymes, which cancer cells use to repair their damaged DNA. By inhibiting this repair mechanism, the drug causes the cancer cells to die.
✅ Key Differentiator: Unlike some other PARP inhibitors, Niranib has shown significant efficacy in patients regardless of their BRCA mutation status.
Indicated for the maintenance treatment of adult patients with:
- Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- First-line maintenance treatment for advanced ovarian cancer.
Dosage Form: 100 mg Capsules.
⚠️ CRITICAL DOSING RULE (Weight & Platelets):
The starting dose is individualized to reduce side effects:
- 300 mg (3 caps) daily: For patients weighing ≥ 77 kg AND platelet count ≥ 150,000/µL.
- 200 mg (2 caps) daily: For patients weighing < 77 kg OR platelet count < 150,000/µL.
🌙 Tip: Take at bedtime to manage potential nausea.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- Severe bone marrow suppression.
- Hypersensitivity to Niraparib.
Regular blood tests (CBC) and blood pressure monitoring are mandatory:
- 🩸 Thrombocytopenia: Low platelet count (risk of bleeding). This is the most common dose-limiting toxicity.
- Anemia & Neutropenia.
- Hypertension: High blood pressure.
- Nausea and fatigue.
What Customers Say
No reviews yet
Your review can be the first!